Peptide therapeutics for rare genetic metabolic diseases

Rhythm Therapeutics (NASDAQ: RYTM) is a biopharmaceutical company focused on developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life‑threatening metabolic disorders. Rhythm’s lead peptide product candidate is setmelanotide, a first‑in‑class melanocortin‑4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Year Invested: 2010
Location: Boston, Mass.

Recent News

April 2, 2019
Rhythm Pharmaceuticals to Present at 18th Annual Needham Healthcare Conference

March 28, 2019
Rhythm Pharmaceuticals Announces Promising Clinical Data in MC4R Pathway Heterozygous Obesity and Strategy for Further Development

March 8, 2019
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

Read More News

Associated Team Members

Neil Exter